Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

Lupin Acquires Anti-Diabetes Trademarks from Boehringer Ingelheim to Strengthen Indian Portfolio

NextEdge Admin

17 Dec 2024

2 min 29 sec

Boehringer Ingelheim International GmbH,type 2 diabetes mellitus,Acquisition

Lupin Limited, a global pharmaceutical major, announced on Friday that it has acquired the anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim International GmbH, strengthening its diabetes portfolio in India. The acquisition will be completed by March next year, with Lupin having already marketed GIBTULIO and GIBTULIO MET since 2016, and AJADUO since 2018, through co-marketing agreements with Boehringer Ingelheim India.

The three drugs, GIBTULIO (empagliflozin), GIBTULIO MET (empagliflozin + metformin), and AJADUO (empagliflozin + linagliptin), belong to the SGLT-2 inhibitor class of oral anti-diabetic medications. They are used to improve glycemic control in adults with type 2 diabetes mellitus, alongside diet and exercise. Empagliflozin also reduces the risk of cardiovascular death in adults with type 2 diabetes and the risk of cardiovascular death and hospitalization due to heart failure in those with chronic kidney disease.

Nilesh Gupta, Managing Director of Lupin, highlighted that this acquisition aligns with the company's ongoing mission to provide quality healthcare solutions, reaffirming their commitment to offering innovative and affordable medications across India. India has an estimated 80 million adults with diabetes, in addition to 25 million pre-diabetics. Due to low awareness, more than 50% of people with diabetes are unaware of their condition, increasing the risk of complications such as heart attack and stroke.

Rajeev Sibal, President of India Region Formulations at Lupin, emphasized the rising prevalence of diabetes and lifestyle diseases, stating that this acquisition would enhance the accessibility and effectiveness of diabetes treatments for millions of patients in India.